Overview

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining chemotherapy with interleukin-2 and GM-CSF may be a more effective treatment for kidney cancer. PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2, vinblastine, and GM-CSF in treating patients with metastatic kidney cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hope Cancer Institute, Inc.
Treatments:
Aldesleukin
Sargramostim
Vinblastine
Criteria
DISEASE CHARACTERISTICS: Histologically proven inoperable, metastatic, or recurrent renal
cell carcinoma Measurable or evaluable disease No brain metastases

PATIENT CHARACTERISTICS: Age: Over 18 Performance status: SWOG 0-2 Life expectancy: At
least 3 months Hematopoietic: Neutrophil count greater than 1,500/mm3 Platelet count
greater than 100,000/mm3 Hepatic: Liver enzymes less than 3 (5 if known liver metastases)
times institutional normal Renal: Creatinine less than 1.5 mg/dL Cardiovascular: Adequate
cardiac function No unstable angina No significant coronary artery disease No heart failure
with New York Heart Association classification III or IV Pulmonary: No evidence of
pulmonary disease (documented normal DLCO and PFT) Other: No prior malignancy except:
Nonmelanoma skin cancer Carcinoma in situ of any kind No pregnant or lactating Fertile
patients must use adequate contraception Normal thyroid functions as evidenced by normal T4
and TSH

PRIOR CONCURRENT THERAPY: Biologic therapy: No more than 1 prior biologic therapy At least
4 weeks since prior biologic therapy Chemotherapy: No more than 1 prior chemotherapy At
least 4 weeks since prior chemotherapy Endocrine therapy: No more than 1 prior hormonal
therapy At least 4 weeks since prior hormonal therapy Radiotherapy: At least 4 weeks since
prior radiation therapy No prior radiation therapy if entire tumor was within radiation
field Surgery: Not specified